Genetesis

Executive Summary

Genetesis is a U.S.-based medical technology company pioneering non-invasive cardiac diagnostics through biomagnetic imaging. Founded in 2013 and headquartered in Mason, Ohio, the company has developed a technology that maps the heart's electrical activity to rapidly assess conditions like myocardial ischemia without radiation or contrast agents. This approach aims to improve the triage and diagnosis of chest pain patients in emergency settings, potentially reducing unnecessary tests and accelerating treatment decisions. While still in early stages, Genetesis addresses a significant unmet need in cardiac care, with its technology offering a novel alternative to traditional stress tests and imaging modalities. The company has not disclosed funding or revenue details, suggesting it remains in development or early commercialization. Its success will depend on regulatory clearances, clinical validation, and market adoption.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for biomagnetic imaging device40% success
• Q4 2026Publication of pivotal clinical trial results50% success
• Q3 2026Strategic partnership or licensing deal with a hospital network35% success